<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091126</url>
  </required_header>
  <id_info>
    <org_study_id>209664</org_study_id>
    <nct_id>NCT04091126</nct_id>
  </id_info>
  <brief_title>Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma</brief_title>
  <acronym>DREAMM 9</acronym>
  <official_title>A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity&#xD;
      of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide),&#xD;
      dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants&#xD;
      with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of&#xD;
      bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by&#xD;
      the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per&#xD;
      dosing schedule. Participants will receive belantamab mafodotin on a schedule that is&#xD;
      dependent on the cohort to which they are assigned. This will be every cycle of VRd, every&#xD;
      other cycle of VRd, or every third cycle of VRd. Belantamab may also be given as a 'split'&#xD;
      dose, which is 50% of the dose on Day 1 and 50% of the dose on Day 8 of a cycle. Participants&#xD;
      will complete an End of Treatment (EOT) visit at the point of study treatment&#xD;
      discontinuation, followed by a Safety Follow-up visit 70 days after EOT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">February 5, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will evaluate different doses/dose schedules of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone, (VRd) in up to 8 cohorts and will determine the Recommended Phase 3 dose (RP3D).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicities (DLTs)</measure>
    <time_frame>Treatment cycle 1 to 3 (each cycle of 21 days)</time_frame>
    <description>The number of participants with DLTs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to an average of 54 months</time_frame>
    <description>AEs and SAEs will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lenalidomide relative dose intensity (RDI ) of treatment with belantamab mafodotin in combination with VRd</measure>
    <time_frame>4 treatment cycles (each cycle of 21 days)</time_frame>
    <description>RDI of treatment with belantamab mafodotin in combination with VRd will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bortezomib RDI of treatment with belantamab mafodotin in combination with VRd</measure>
    <time_frame>4 treatment cycles (each cycle of 21 days)</time_frame>
    <description>RDI of treatment with belantamab mafodotin in combination with VRd will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative administered dose of belantamab mafodotin treatment in combination with VRd</measure>
    <time_frame>4 treatment cycles (each cycle of 21 days)</time_frame>
    <description>Cumulative administered dose of belantamab mafodotin in treatment in combination with VRd will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of belantamab mafodotin</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of total monoclonal antibody (mAb)</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of microtubule inhibitor monomethyl auristatin-F with a cysteine linker (cys-mcMMAF)</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve (AUC) of belantamab mafodotin</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of monoclonal antibody (mAb)</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of cys-mcMMAF</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Blood samples will be collected at indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Serum samples for the analysis of anti-belantamab mafodotin antibodies will be collected. The samples will be tested for anti-belantamab mafodotin antibodies using a tiered-testing scheme consisting of validated screening, confirmation, and titration assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of ADAs against belantamab mafodotin</measure>
    <time_frame>Up to an average of 52 months</time_frame>
    <description>Serum samples for the analysis of anti-belantamab mafodotin antibodies will be collected. The samples will be tested for anti-belantamab mafodotin antibodies using a tiered-testing scheme consisting of validated screening, confirmation, and titration assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 52 months</time_frame>
    <description>ORR is defined as the percentage of participants with a confirmed partial response (PR) or better based on the response assessed by the investigator using International Myeloma Working Group (IMWG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>Up to 52 months</time_frame>
    <description>CRR is defined as the percentage of participants with a confirmed complete response (CR) or better based on the response assessed by the investigator using IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Very Good Partial Response (VGPR) or better</measure>
    <time_frame>Up to 52 months</time_frame>
    <description>Rate of VGPR or better is defined as the percentage of participants with a confirmed VGPR or better based on the response assessed by the investigator using IMWG criteria.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.9 milligram /kilogram (mg/kg) three -weekly (Q3W) dose of belantamab mafodotin intravenously (IV) on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.9 mg/kg four-weekly (Q4W) dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.4 mg/kg six-weekly (Q6W) dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.4 mg/kg eight-weekly (Q8W) dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.9 mg/kg Q8W dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin intravenously on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.0 mg/kg Q4W dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin intravenously on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.4 mg/kg Q4W dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: belantamab mafodotin 1.9 or 2.5 mg/kg Q9/12W+VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on emerging data, participants will receive either 1.9 mg/kg or 2.5 mg/kg Q9W dose of belantamab mafodotin intravenously on Day 1 of every third 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive either 1.9 mg/kg or 2.5 mg/kg Q12W dose of belantamab mafodotin intravenously on Day 1 of every third 28-day cycle in combination with Rd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort7:belantamab mafodotin 1.9/2.5mg/kg Q6/8W (split)+VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on emerging data, participants will receive a total dose of either 1.9 mg/kg or 2.5 mg/kg of belantamab mafodotin intravenously (split in to two equal doses of 0.95 mg/kg or 1.25 mg/kg to be given on Day 1 and Day 8) Q6W of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive a total dose of either 1.9 mg/kg or 2.5 mg/kg of belantamab mafodotin intravenously (split in to two equal doses of 0.95 mg/kg or 1.25 mg/kg to be given on Day 1 and Day 8) Q8W of every other 28-day cycle in combination with Rd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: belantamab mafodotin 2.5 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on emerging data, participants will receive 2.5 mg/kg Q6W dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 2.5 mg/kg Q8W dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab mafodotin</intervention_name>
    <description>Selected doses of belantamab mafodotin will be administered as intravenous infusion.</description>
    <arm_group_label>Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 6: belantamab mafodotin 1.9 or 2.5 mg/kg Q9/12W+VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 8: belantamab mafodotin 2.5 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort7:belantamab mafodotin 1.9/2.5mg/kg Q6/8W (split)+VRd/Rd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib will be administered subcutaneously or intravenously 1 hour after the belantamab mafodotin infusion.</description>
    <arm_group_label>Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 6: belantamab mafodotin 1.9 or 2.5 mg/kg Q9/12W+VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 8: belantamab mafodotin 2.5 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort7:belantamab mafodotin 1.9/2.5mg/kg Q6/8W (split)+VRd/Rd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.</description>
    <arm_group_label>Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 6: belantamab mafodotin 1.9 or 2.5 mg/kg Q9/12W+VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 8: belantamab mafodotin 2.5 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort7:belantamab mafodotin 1.9/2.5mg/kg Q6/8W (split)+VRd/Rd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.</description>
    <arm_group_label>Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 6: belantamab mafodotin 1.9 or 2.5 mg/kg Q9/12W+VRd/Rd</arm_group_label>
    <arm_group_label>Cohort 8: belantamab mafodotin 2.5 mg/kg Q6/8W + VRd/Rd</arm_group_label>
    <arm_group_label>Cohort7:belantamab mafodotin 1.9/2.5mg/kg Q6/8W (split)+VRd/Rd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be over 18 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Diagnosis of multiple myeloma with a requirement for treatment as documented per&#xD;
             international myeloma working group (IMWG) criteria.&#xD;
&#xD;
          -  Must have at least one aspect of measurable disease, defined as one of the following:&#xD;
&#xD;
          -  Urine M-protein excretion &gt;=200 mg/24 hours (&gt;=0.2 gram [g]/24 hours), or&#xD;
&#xD;
          -  Serum M-protein concentration &gt;=0.5 grams per deciliter (g/dL) (&gt;=5.0 gram per liter&#xD;
             [g/L]), or&#xD;
&#xD;
          -  Serum free light chain (FLC) assay: involved FLC level &gt;=10 milligrams per deciliter&#xD;
             (mg/dL) (&gt;=100 milligram per liter [mg/L]) and an abnormal serum free light chain&#xD;
             ratio (&lt;0.26 or &gt;1.65).&#xD;
&#xD;
          -  Not a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT)&#xD;
             due to presence of significant comorbid condition(s), such as cardiac, pulmonary or&#xD;
             other major organ dysfunction that are likely to have a negative impact on&#xD;
             tolerability of high dose chemotherapy with stem cell transplantation, as judged by&#xD;
             the investigator.&#xD;
&#xD;
          -  Eastern cooperative oncology group (ECOG) status of 0-2&#xD;
&#xD;
          -  Adequate organ system functions as defined by the laboratory assessments listed as&#xD;
             following: Absolute neutrophil count (ANC) &gt;=1.5 x 10^9/L; Hemoglobin &gt;=8.0 g/dL;&#xD;
             Platelets &gt;=75 x 10^9/L; Total bilirubin &lt;=1.5 x upper limit of normal (ULN);&#xD;
             (Isolated bilirubin &gt;1.5 x ULN is acceptable if bilirubin is fractionated and direct&#xD;
             bilirubin is &lt;35%); Alanine aminotransferase (ALT) &lt;=2.5 x ULN; eGFR &gt;=30&#xD;
             mL/minute/1.73 meter^2; Urine Dipstick for protein OR Albumin/creatinine ratio (from&#xD;
             spot urine)- Negative/trace (if &gt;=1 plus only eligible if confirmed &lt;=500 mg/gram (56&#xD;
             mg/millimoles [mmol]) by albumin/creatinine ratio (spot urine from first void); Left&#xD;
             Ventricular Ejection Fraction (LVEF) by echocardiogram (ECHO) of &gt;=35% participants&#xD;
             with low LVEF (per institutional standards), consider referring to cardiology per&#xD;
             local standards of care.&#xD;
&#xD;
          -  Male and/or female&#xD;
&#xD;
          -  Contraceptive use by women should be consistent with local regulations regarding the&#xD;
             methods of contraception for those participating in clinical studies. A female&#xD;
             participant is eligible to participate if she is not pregnant or breastfeeding, and at&#xD;
             least 1 of the following conditions applies:&#xD;
&#xD;
          -  Is NOT a woman of childbearing potential (WOCBP) or Due to lenalidomide being a&#xD;
             thalidomide analogue with risk for embryofetal toxicity and prescribed under a&#xD;
             pregnancy prevention/controlled distribution program, and bortezomib having the&#xD;
             potential to cause fetal harm, WOCBP participants will be eligible if they commit to&#xD;
             either: abstain continuously from heterosexual sexual intercourse as their preferred&#xD;
             and usual lifestyle (abstinent on a long term and persistent basis) and agree to&#xD;
             remain abstinent OR to use birth control as follows: Two methods of reliable birth&#xD;
             control (one method that is highly effective and one additional effective (barrier)&#xD;
             method), beginning 4 weeks prior to initiating treatment with lenalidomide, during&#xD;
             therapy, during dose interruptions and continuing for 4 weeks following&#xD;
             discontinuation of lenalidomide treatment. Thereafter, WOCBP participants must use one&#xD;
             method of reliable birth control that is highly effective for a further 3 months&#xD;
             following discontinuation of belantamab mafodotin, or a further 6 months following&#xD;
             discontinuation of bortezomib, whichever is longer. WOCBP must also agree not to&#xD;
             donate eggs (ova, oocytes) for the purpose of reproduction during treatment, during&#xD;
             dose interruptions and for 28-days following the last dose of lenalidomide, 4 months&#xD;
             following discontinuation of belantamab mafodotin treatment or 7-months following the&#xD;
             last dose of bortezomib, whichever is longer. Two negative pregnancy tests must be&#xD;
             obtained prior to initiating therapy. The first test should be performed within 10-14&#xD;
             days and the second test within 24 hours prior to prescribing the start of&#xD;
             lenalidomide therapy.&#xD;
&#xD;
        The participant should not receive lenalidomide until the investigator has verified that&#xD;
        the results of these pregnancy tests are negative. The investigator should evaluate the&#xD;
        effectiveness of the contraceptive method in relationship to the first dose of study&#xD;
        intervention. The Investigator is responsible for review of medical history, menstrual&#xD;
        history, and recent sexual activity to decrease the risk for inclusion of a woman with an&#xD;
        early undetected pregnancy.&#xD;
&#xD;
          -  Contraceptive use by men should be consistent with local regulations regarding the&#xD;
             methods of contraception for those participating in clinical studies&#xD;
&#xD;
          -  Male participants are eligible to participate if they agree to the following from the&#xD;
             time of first dose of study treatment until 28-days after the last dose of&#xD;
             lenalidomide, 4-months after the last dose of bortezomib, or 6 months after the last&#xD;
             dose of belantamab mafodotin, whichever is longer, to allow for clearance of any&#xD;
             altered sperm: Refrain from donating sperm - Plus either: - Be abstinent from&#xD;
             heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long&#xD;
             term and persistent basis) and agree to remain abstinent OR Must agree to use&#xD;
             contraception/barrier as detailed below: Agree to use a male condom, even if they have&#xD;
             undergone a successful vasectomy, and female partner to use an additional highly&#xD;
             effective contraceptive method with a failure rate of &lt;1% per year when having sexual&#xD;
             intercourse with a WOCBP. Male participants should also use a condom when having&#xD;
             sexual intercourse with pregnant females.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoldering multiple myeloma (SMM).&#xD;
&#xD;
          -  Prior systemic therapy for multiple myeloma, or SMM. NOTE: An emergency course of&#xD;
             steroids (defined as no greater than 40 mg of dexamethasone, or equivalent per day for&#xD;
             a maximum of 4 days (that is, a total of 160 mg) is permitted. NOTE: Focal palliative&#xD;
             radiation is permitted prior to enrollment, provided that it occurred at least 2 weeks&#xD;
             prior to the first dose of study drug, that the participant has recovered from&#xD;
             radiation-related toxicities, and that the participant did not require corticosteroids&#xD;
             for radiation-induced adverse events.&#xD;
&#xD;
          -  Participant is eligible for high dose chemotherapy with ASCT, as determined by a&#xD;
             frailty score of 0 as assessed by the IMWG frailty index.&#xD;
&#xD;
          -  Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the&#xD;
             national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE)&#xD;
             Version 5.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  Presence of active renal condition (infection, requirement for dialysis or any other&#xD;
             significant condition that could affect participant's safety). Participants with&#xD;
             isolated proteinuria resulting from multiple myeloma (MM) are eligible, provided they&#xD;
             fulfil criteria.&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other&#xD;
             conditions (including lab abnormalities) that could interfere with participant's&#xD;
             safety, obtaining informed consent or compliance to the study procedures.&#xD;
&#xD;
          -  Evidence of active mucosal or internal bleeding uncontrolled by local therapy and not&#xD;
             explained by reversible coagulopathy.&#xD;
&#xD;
          -  Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic&#xD;
             gallstones, or otherwise stable chronic liver disease as per the Investigator's&#xD;
             assessment).&#xD;
&#xD;
          -  Participants with previous or concurrent malignancies other than multiple myeloma are&#xD;
             excluded. Exceptions are surgically treated cervical carcinoma in situ, or any other&#xD;
             malignancy that has been considered medically stable for at least 2 years. The&#xD;
             participant must not be receiving active therapy, other than hormonal therapy for this&#xD;
             disease. Note: Participants with curatively treated non-melanoma skin cancer are&#xD;
             allowed without a 2-year restriction.&#xD;
&#xD;
          -  Evidence of cardiovascular risk including any of following: Evidence of current&#xD;
             clinically significant untreated arrhythmias, including clinically significant&#xD;
             electrocardiogram (ECG) abnormalities including second degree (Mobitz Type II) or&#xD;
             third degree atrioventricular (AV) block; History of myocardial infarction, acute&#xD;
             coronary syndromes (including unstable angina), coronary angioplasty, or stenting or&#xD;
             bypass grafting within 3 months of Screening.; Class III or IV heart failure as&#xD;
             defined by the New York Heart Association (NYHA) functional classification system;&#xD;
             Uncontrolled hypertension.&#xD;
&#xD;
          -  Active infection requiring treatment.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb),&#xD;
             at Screening or within 3 months prior to first dose of study treatment. Note:&#xD;
             Participants with positive hepatitis C antibody due to prior resolved disease can be&#xD;
             enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.&#xD;
&#xD;
          -  Positive hepatitis C antibody test result.&#xD;
&#xD;
          -  Current corneal epithelial disease except for mild punctate keratopathy. Note:&#xD;
             Participants with mild punctate keratopathy are allowed.&#xD;
&#xD;
          -  Intolerance or contraindications to anti-viral prophylaxis.&#xD;
&#xD;
          -  Unable to tolerate antithrombotic prophylaxis.&#xD;
&#xD;
          -  AL amyloidosis (light chain amyloidosis), active polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal plasma proliferative disorder, skin changes (POEMS)&#xD;
             syndrome or active plasma cell leukemia at the time of screening.&#xD;
&#xD;
          -  Exhibiting clinical signs of or has a known history of meningeal or central nervous&#xD;
             system involvement by multiple myeloma.&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to&#xD;
             drugs chemically related to belantamab mafodotin, or any of the components of the&#xD;
             study treatment.&#xD;
&#xD;
          -  Use of an investigational drug within 14 days or five half-lives (whichever is longer)&#xD;
             preceding the first dose of study drug.&#xD;
&#xD;
          -  Plasmapheresis within 7 days prior to the first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yuma</city>
        <state>Arizona</state>
        <zip>85364</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abhinav Chandra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Al-Ola Abdallah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Saad Usmani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Hurd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Natalie Callander</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wojciech Janowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Low</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hang Quach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Irwindeep Sandhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Martha Louzada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Arleigh McCurdy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poitiers cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Leleu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rennes cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Decaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Raab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Britta Besemer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Guenther</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <state>Rheinland-Pfalz</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joerg Thomalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Katja Weisel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Cavo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maurizio Martelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luca Baldini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul, Korea</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chang Ki Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Youngil Koh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jin Seok Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kihyun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marek Hus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Albert Oriol Rocafiguera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Rosinol Dachs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Rodriguez Otero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mlaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ricarda Garca Snchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Rodriguez Otero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pozuelo De Alarcn/Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Arnzazu Alonso Alonso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Enrique Mara Ocio San Miguel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Jenner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Headington, Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Karthik Ramasamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mamta Garg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Majid Kazmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bortezomib</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>VRd</keyword>
  <keyword>Belantamab mafodotin</keyword>
  <keyword>Newly diagnosed multiple myeloma</keyword>
  <keyword>RP3D</keyword>
  <keyword>DREAMM 9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

